11.26

1.62% 0.18

Adma Biologics Inc (ADMA)

Overview News Price History Option Chain Financials Discussions Forecast

Adma Biologics Inc stock is traded at $11.26, with a volume of 4.16M. It is up +1.62% in the last 24 hours and down -0.62% over the past month. ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.

Previous Close:

$11.08

Open:

$11.08

24h Volume:

4.16M

Relative Volume:

0.75

Market Cap:

$2.62B

Revenue:

$510.17M

Net Income/Loss:

$146.93M

P/E Ratio:

18.80

EPS:

0.599

Net Cash Flow:

$27.51M

1W Performance:

+2.27%

1M Performance:

-0.62%

6M Performance:

-25.82%

1Y Performance:

-49.57%

1-Day Range:

$10.99

$11.42

1-Week Range:

$10.63

$11.42

52-Week Range:

$7.2101

$25.67

Adma Biologics Inc Stock (ADMA) Company Profile

Name

Adma Biologics Inc

Sector

Healthcare (1108)

Industry

Biotechnology (619)

Phone

(201) 478-5552

Address

C/O ADMA BIOLOGICS, INC., RAMSEY

Employee

647

Twitter

@AdmaBiologics

Next Earnings Date

2026-05-06

Latest SEC Filings

ADMA's Discussions on Twitter

Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADMA Adma Biologics Inc	11.26	2.57B	510.17M	146.93M	27.51M	0.599
VRTX Vertex Pharmaceuticals Inc	430.29	110.67B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	751.57	80.98B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	780.25	49.00B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	305.54	41.87B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	300.80	33.28B	5.36B	287.73M	924.18M	2.5229

Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Initiated	Canaccord Genuity	Buy
Mar-26-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jul-19-23	Resumed	Raymond James	Strong Buy
Oct-13-22	Initiated	Mizuho	Buy
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight
Jun-04-19	Initiated	Jefferies	Buy
Apr-15-19	Reiterated	H.C. Wainwright	Buy
Feb-07-19	Resumed	H.C. Wainwright	Buy
Dec-11-17	Reiterated	Maxim Group	Buy
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy
May-13-15	Reiterated	Maxim Group	Buy
Dec-08-14	Initiated	Oppenheimer	Outperform
Dec-01-14	Reiterated	Maxim Group	Buy

View All

Adma Biologics Inc Stock (ADMA) Latest News

Apr 24, 2026

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Lufax Holding Ltd Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.

Apr 24, 2026

ADMA Biologics Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.

Apr 24, 2026

ADMA Biologics drops amid short report from Culper Research - MSN

Apr 24, 2026